Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test tracks lung cancer resistance in Real-World study

NCT ID NCT07475637

Knowledge-focused Sponsor: Faculty of Medicine of Tunis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a simple blood test (liquid biopsy) can detect a specific resistance mutation called T790M in patients with advanced non-small cell lung cancer whose tumors stopped responding to initial targeted therapy. Researchers followed 70 patients in Tunisia, collecting blood samples and medical records to see how often the mutation appeared and if repeat testing improved detection. The goal was to understand how useful liquid biopsy is for monitoring resistance in everyday clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study included patients with advanced non-small cell lung cancer consulting in different hospitals in Tunisia (The Military Hospital of Tunis, Salah Azaiez Institute, Abderhamen Mami Hospital, Jendouba Hospital, Charles Nicolle Hospital of Tunis...) and referred to the Pathology Department of Charles Nicolle Hospital of Tunis for EGFR T790M monitoring using liquid biopsy.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed advanced (stage IIIB/IV) non-small cell lung cancer * Documented activating EGFR mutations * Disease progression on first- or second-generation EGFR TKIs Exclusion Criteria: * Prior treatment with third-generation EGFR TKIs before plasma sampling * Lack of follow-up clinical data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Pathology Department, Charles Nicolle Hospital of Tunis

    Tunis, 1007, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.